Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

U.S.$) 2009 2008 2009 2008 ------------------------------------------------------------------------- GAAP net loss $ (15,633) $ (76,963) $ (22,868) $ (741,176) Interest expense on long-term debt 9,068 10,639 38,039 44,490 Income tax expense (recovery) (1,532) (2,577) 6,037 (12,892) Depreciation and Amortization 9,460 9,327 37,026 38,174 ------------------------------------------------------------------------- EBITDA 1,363 (59,574) 58,234 (671,404) Adjustments: Non-recurring revenue, net of license fees(a) (53) (352) (25,556) (910) Restructuring related charges(b) (309) 1,583 3,820 10,407 In-process and non-recurring research and development charges(c) 500 313 1,866 3,438 Non-recurring supply/distribution agreement termination costs(b) - - - 500 Stock-based compensation(d) 408 458 1,579 2,439 Litigation expenses(g) 684 177 3,297 2,670 Foreign exchange loss (gain)(h) 385 1,032 1,612 (540) Investment and other income 196 498 122 (1,255) Write-downs of investments and other long-lived assets(i) 3,090 12,247 3,090 24,870 Write-down of goodwill(i) - 50,285 - 649,685 Write-downs and other non-recurring deferred financing costs(f) - 3,665 643 17,209 Non-recurring char
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Breakthrough in light sources for new quantum technology 2
... Terrace, Ill. - Browser-based attacks are surging and may pose ... That is one of the key findings of the second ... CompTIA , the Computing Technology Industry Association. , ,The ... plagued by one or more browser-based attacks in the last ...
... Wis. High-speed Internet access is now a reality ... non-line-of-sight wireless broadband system. Toronto-based WaveRider Communications Inc. ... and Oakdale Electric Cooperative to implement ... previously lacked access to broadband Internet services. , ,The ...
... MADISON - University of Wisconsin-Madison faculty and staff interested ... resource to help them through the process of taking ... for New Business Ventures at the University of Wisconsin-Madison," ... Web site of the UW-Madison Office of Corporate Relations ...
Cached Biology Technology:Browser-based attacks may pose next big IT security nightmare 2Rural Wisconsin town gets high-speed Internet access 2New guide offers assistance to UW-Madison entrepreneurs 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... This news release is available in German . ... are key players in the natural nitrogen cycle on ... these specialist bacteria were thought to depend on nitrite ... scientists led by Holger Daims, a microbiologist at the ... can use hydrogen as an alternative source of energy. ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... 12,000 new animalsmicroscopic Elkhorn coral larvae harvested by ... an international collaborative program to raise the threatened ... return the animals, once they are grown, to ... Reproductive Scientist Dr. Mary Hagedorn and Invertebrates Keeper ...
... RIVERSIDE, Calif. While prescription medications work successfully to cure ... of the same drug can cause an adverse reaction or ... led by Sean Cutler, an assistant professor of plant cell ... be analyzed by studying much simpler organisms like plants. ...
... Institute of Technology has been selected by the New ... in Technology Education Award, in recognition of the Institutes ... technological university. Stevens will be honored by the NJTC ... Science Center in Jersey City, N.J., November 15, 2007. ...
Cached Biology News:Smithsonian scientists working to save microscopic threatened species 2Plants can be used to study how and why people respond differently to drugs 2Stevens wins Excellence in Technology Education Award 2
... at its Best: DASGIPs Process Control ... Changes & comprehensive documentation for cultivation ... auch as pH, dissolved oxygen, temperature ... changeable online. Profiles, e.g. constant or ...
... LC Sciences provides a genome-wide microRNA (miRNA) ... proprietary probe design, which enable highly sensitive ... We have standard arrays for mature miRNA ... version of the Sanger miRBase database (Release ...
... acid synthetic peptide whose sequences are derived from mouse resistin protein. ... S(21) - S - M - P - L - C ... I - D - K - K - I - K ... be used for neutralization and control experiments with the polyclonal antibody ...
... 2D Proteomic Imaging System, Basic Package ... Wide Dynamic Range: The ProXPRESS 2D Proteomic ... imaging system for both proteomic and general ... unparalleled flexibility, enabling the use of all ...
Biology Products: